CCI vs PPCB · P/E 40, rev $6.57B vs P/E 0.0, $3.9M cap
Crown Castle (CCI) versus Propanc Biopharma, Inc. Common Stock (PPCB) — a side-by-side from cached financials, not a winner call.
Crown Castle (CCI) is a reit - specialty company listed on US.
Propanc Biopharma, Inc. Common Stock (PPCB) is a biotechnology company listed on NASDAQ.
Latest reported CCI revenue for 2024-12-31 was $6.57B. Net income was -$3.90B. Revenue was down 5.9% from 2023-12-31 to 2024-12-31. CCI currently screens at market cap $40.93B and trailing P/E 39.6.
PPCB does not have a complete income-statement cache yet.
CCI currently screens at market cap $40.93B and trailing P/E 39.6. PPCB currently screens at market cap $3.9M and trailing P/E 0.0.
Not investment advice. Open the CCI and PPCB stock pages for the full models.
Not investment advice.